At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALT Altimmune, Inc.
Market Closed 02-14 16:00:00 EST
6.37
+0.14
+2.25%
盘后6.44
+0.07+1.10%
19:59 EST
High6.53Low6.17Vol2.43M
Open6.22D1 Closing6.23Amplitude5.78%
Mkt Cap453.06MTradable Cap448.81MTotal Shares71.12M
T/O15.44MT/O Rate3.45%Tradable Shares70.46M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
GlobeNewswire  ·  02-12
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
Altimmune call volume above normal and directionally bullish
TIPRANKS  ·  02-12
Altimmune call volume above normal and directionally bullish
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
Business Wire  ·  02-11
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
PR Newswire  ·  02-07
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones  ·  02-06
Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns
Simply Wall St.  ·  02-04
With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns
B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)
TIPRANKS  ·  01-28
B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
Business Wire  ·  01-24
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones  ·  01-23
Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
GlobeNewswire  ·  01-22
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
Altimmune call volume above normal and directionally bullish
TIPRANKS  ·  01-18
Altimmune call volume above normal and directionally bullish
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
PR Newswire  ·  01-17
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
PR Newswire  ·  01-16
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire  ·  01-10
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Stifel Initiates Altimmune at Buy With $18 Price Target
MT Newswires Live  ·  01-08
Stifel Initiates Altimmune at Buy With $18 Price Target
Evercore ISI Keeps Their Buy Rating on Altimmune (ALT)
TIPRANKS  ·  01-08
Evercore ISI Keeps Their Buy Rating on Altimmune (ALT)
Altimmune Inc : Stifel Initiates Coverage With Buy Rating; Price Target $18
THOMSON REUTERS  ·  01-08
Altimmune Inc : Stifel Initiates Coverage With Buy Rating; Price Target $18
Innovative Breakthrough in Metabolic Disease Treatment: Annabel Samimy’s Buy Rating on Altimmune’s Pemvidutide
TIPRANKS  ·  01-08
Innovative Breakthrough in Metabolic Disease Treatment: Annabel Samimy’s Buy Rating on Altimmune’s Pemvidutide
Altimmune initiated with a Buy at Stifel
TIPRANKS  ·  01-08
Altimmune initiated with a Buy at Stifel
BUZZ-Viking set to double in 'challenging' year for obesity drug developers
Reuters  ·  01-01
BUZZ-Viking set to double in 'challenging' year for obesity drug developers

Introduction

Company Name.
Altimmune, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Issue price:
--